OC
VNDA icon

Oppenheimer & Co’s Vanda Pharmaceuticals VNDA Stock Holding History

Oppenheimer & Co’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-15,480
Closed -$285K – 1390
2019
Q1 		$285K Sell
15,480
-182
-1% -$4.15K 0.01% 1057
2018
Q4 		$409K Sell
15,662
-1,278
-8% -$30K 0.01% 815
2018
Q3 		$389K Buy
+16,940
New +$346K 0.01% 961
2013
Q3 		– Sell
-40,000
Closed -$323K – 1371
2013
Q2 		$323K Buy
+40,000
New +$269K 0.01% 898

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Oppenheimer & Co's VNDA Position: Q2 2019 in Review

Oppenheimer & Co sold out of Vanda Pharmaceuticals (VNDA) in Q2 2019, closing a stake of 15,480 shares — an estimated $285K sold.

Oppenheimer & Co first reported a position in VNDA in Q2 2013 and held it in 4 quarters. The position peaked at $409K in Q4 2018. 164 funds tracked by Wall St. Rank hold VNDA as of Q2 2019.

  • Oppenheimer & Co reported no remaining Vanda Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Oppenheimer & Co sold 15,480 Vanda Pharmaceuticals shares in Q2 2019, an estimated $285K.
  • Oppenheimer & Co first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Oppenheimer & Co's Vanda Pharmaceuticals position peaked at $409K in Q4 2018.
  • 164 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2019.

Based on Oppenheimer & Co's 13F filing for Q2 2019, filed 9 Aug 2019.